PharmaMar Endures Second Recent Setback With Phase III Ovarian Cancer Failure
Executive Summary
Zepsyre did not show a PFS advantage measured against a comparator regimen in platinum-resistant ovarian cancer, but the novel chemotherapy is being tested in nine other cancers.
You may also be interested in...
CHMP Negative On PharmaMar's Aplidin In Multiple Myeloma
Clouds are gathering over Spanish firm PharmaMar as the EU's CHMP rejects its multiple myeloma therapy Aplidin. Its reasons are not yet forthcoming.
Lynparza Poised For Growth With Broad Ovarian Cancer Approval
AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.
PharmaMar Aims For A Second Marketed Product With EU Aplidin Filing
Spanish company PharmaMar has filed for approval of its anticancer Aplidin in the EU, which if successful would be its second product to reach the market.